Takeda Pharmaceutical Company Ltd
🇯🇵Japan
- Country
- 🇯🇵Japan
- Ownership
- -
- Established
- 1925-01-01
- Employees
- -
- Market Cap
- $47.5B
- Website
- http://www.takeda.co.jp/
Comparison of TAK-875 to Placebo as an Add-on to Glimepiride in Patients With Type 2 Diabetes
Phase 3
Terminated
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2013-04-11
- Last Posted Date
- 2016-06-01
- Lead Sponsor
- Takeda
- Target Recruit Count
- 33
- Registration Number
- NCT01829477
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
- First Posted Date
- 2013-04-11
- Last Posted Date
- 2016-06-01
- Lead Sponsor
- Takeda
- Target Recruit Count
- 90
- Registration Number
- NCT01829464
- Locations
- 🇺🇸
Apex Medical Research, MI, Inc, Chicago, Illinois, United States
Phase 1b Study Investigating Safety & Immunogenicity of TDV Given Intradermally by Needle or Needle-Free PharmaJet Injector
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- Biological: TDVDrug: Placebo
- First Posted Date
- 2013-01-10
- Last Posted Date
- 2019-07-18
- Lead Sponsor
- Takeda
- Target Recruit Count
- 67
- Registration Number
- NCT01765426
- Locations
- 🇺🇸
University of Texas Medical Branch, Galveston, Texas, United States
🇺🇸Group Health Research Institute, Seattle, Washington, United States
The Influence of Febuxostat on Coronary Artery Endothelial Dysfunction in Participants With Chronic Stable Angina
Phase 4
Completed
- Conditions
- Coronary Artery Disease
- Interventions
- First Posted Date
- 2013-01-09
- Last Posted Date
- 2016-04-13
- Lead Sponsor
- Takeda
- Target Recruit Count
- 30
- Registration Number
- NCT01763996
SYR-472 Open-label Study
- First Posted Date
- 2012-12-18
- Last Posted Date
- 2023-12-11
- Lead Sponsor
- Takeda
- Target Recruit Count
- 14
- Registration Number
- NCT01751360
Evaluation of the Efficacy, Safety and Tolerance of Experimental Morning-only MOVIPREP® Bowel Preparation in Comparison With Split-dose With Nocturnal Pause MOVIPREP® Bowel Preparation
Phase 3
Completed
- Conditions
- Bowel Preparation Prior to Endoscopic, Radiological and Other Examinations as Well as to Surgical Procedures Which Require Empty Bowel.
- Interventions
- First Posted Date
- 2012-11-26
- Last Posted Date
- 2014-05-15
- Lead Sponsor
- Takeda
- Target Recruit Count
- 140
- Registration Number
- NCT01732692
Impact of SC vs IM Administration of DENVax (TDV) on Safety and Immunogenicity
Phase 1
Completed
- Conditions
- Dengue Fever
- Interventions
- Biological: TDV
- First Posted Date
- 2012-11-20
- Last Posted Date
- 2019-07-18
- Lead Sponsor
- Takeda
- Target Recruit Count
- 80
- Registration Number
- NCT01728792
- Locations
- 🇺🇸
SUNY Upstate Medical University, Syracuse, New York, United States
A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma
Phase 3
Active, not recruiting
- Conditions
- Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2012-10-23
- Last Posted Date
- 2025-03-12
- Lead Sponsor
- Takeda
- Target Recruit Count
- 1334
- Registration Number
- NCT01712490
A Double-blind, Parallel Group, Comparative Study of Coadministration AD-4833 and SYR-322
Phase 4
Completed
- Conditions
- Diabetes Mellitus
- Interventions
- Drug: AD-4833 30 mgDrug: AD-4833 15 mgDrug: Placebo
- First Posted Date
- 2012-09-18
- Last Posted Date
- 2023-08-31
- Lead Sponsor
- Takeda
- Target Recruit Count
- 207
- Registration Number
- NCT01686711
A Safety and Efficacy Study of Ramelteon Tablets for Sublingual Administration (TAK-375SL) in the Maintenance Treatment of Bipolar 1 Disorder
Phase 3
Withdrawn
- Conditions
- Bipolar Disorder
- Interventions
- First Posted Date
- 2012-09-14
- Last Posted Date
- 2013-01-23
- Lead Sponsor
- Takeda
- Registration Number
- NCT01685151
© Copyright 2025. All Rights Reserved by MedPath